• Nomenclature. Two names have been widely used for this compound, \"HA-1077\" and \"Fasudil\". These names have been variously and inconsistently applied to the free base, the monohydrochloride salt (the only form that LC Labs currently sells) and the dihydrochloride salt forms.
• The monohydrochloride salt is the form used to prepare formulations of this drug for clinical use. Note that the solubility properties of the mono- and di-HCl salts are different.
• Kinase inhibitor; has antivasospastic properties.-- Asano, T., et al. \"Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinases.\" Br. J. Pharmacol. 98: 1091-1100 (1989).-- Sasaki, Y. and Sasaki, Y. \"Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilator.\" Biochem. Biophys. Res. Commun. 171: 1182-1187 (1990).-- Seto, M., et al. \"Effects of HA 1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle.\" Eur. J. Pharmacol. 195: 267-272 (1991).-- Shibuya, O., et al. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs. Acta Neurochir. 90: 53 (1988).-- Shirotani, M. et al. \"A new type of vasodilator, HA 1077, an isoquinoline derivative, inhibits proliferation of bovine vascular smooth muscle cells in culture.\" J. Pharmacol. Exp. Ther. 259: 738-744 (1991).-- Swärd, K. et al. \"Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum.\" J. Physiol. 522: 33-49 (2000).-- Davies, S.P. et al. \"Specificity and mechanism of action of some commonly used protein kinase inhibitors.\" Biochem. J. 351: 95-105 (2000).
• Potencies for inhibition of various kinases by Fasudil:

  Enzyme	IC50	Ki	Reference
  Rho-associated Kinase II	1.9 µM		Davies, S.P. et al.
  Protein Kinase C-Related Kinase 2	4 µM		Davies, S.P. et al.
  Mitogen- and Stress-Activated Protein Kinase 1	5 µM		Davies, S.P. et al.
  Mitogen Activated Protein Kinase-Activated Protein Kinase 1b	5 µM		Davies, S.P. et al.
  Rho-associated Kinase	10.7 µM		Swärd, K. et al.
  Myosin Light Chain Kinase	95.2 µM		Swärd, K. et al.
  Protein Kinase C	425 µM		Swärd, K. et al.
  Cyclic AMP-Dependent Protein Kinase		1.6 µM	Asano, T. et al.
  Cyclic GMP-Dependent Protein Kinase		1.6 µM	Asano, T. et al.
  Myosin Light Chain Kinase		36 µM	Asano, T. et al.

• This monohydrochloride salt form is the active ingredient in drug formulations marketed in Japan to treat cerebral vasospasm following surgery for subarachnoid hemorrhage and associated cerebral ischemic symptoms. Zhao, J. et al. \"Effect of Fasudil Hydrochloride, a Protein Kinase Inhibitor, on Cerebral Vasospasm and Delayed Cerebral Ischemic Symptoms After Aneurysmal Subarachnoid Hemorrhage.\" Neurologia Medico-Chirurgica 46: 421-428 (2006). Also, the monohydrochloride form has been or presently is in human clinical trials for treatment of acute cerebral thrombosis, subarachnoid hemorrhage, and angina pectoris.
• Related CAS numbers: 103745-39-7 for fasudil free base and 203911-27-7 for HA-1077 dihydrochloride salt.
• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

Related Terms:

Storage

Solubility

Disposal